REGN
WAITRegeneron Pharmaceuticals, Inc.
$695.42
+0.03%delayed
News – · Trend ▲ · inside triggers –
Expected move (1d)
▼ $677.80to$713.04 ▲
ATR ±$17.62 (+2.53%)Implied ±$44.20 (+6.36%)
Entry Reference
Price / prev close$695.42 / $695.18
Day range$691.00 – $702.60
52-wk range$541.00 – $821.11(55%)
Volume vs avg1.01×
ATR (14d)$17.62
MA 8 / 21$670.53 / $663.21
MA 50 / 200$638.86 / $707.84
Call ▲ / Put ▼ trigger$699.34 / $691.02
+1 / +2 ATR$713.04 / $730.67
-1 / -2 ATR$677.80 / $660.17
Support: 691.13 677.92 668.85
Resistance: 727.88 737.34 753.79
Near-the-money contracts
exp 2026-07-31Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 685 | $27.10 | 86% | 0.61 | -4.58 | 3 |
| 690 | $24.70 | 87% | 0.56 | -4.77 | 108 |
| 695 | $21.60 | 85% | 0.52 | -4.70 | 5 |
| 700 | $19.25 | 85% | 0.47 | -4.69 | 21 |
| 705 | $18.25 | 90% | 0.43 | -4.87 | 6 |
| 710 | $15.30 | 86% | 0.38 | -4.51 | 2 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 660 | $6.95 | 81% | -0.17 | -2.77 | 4 |
| 670 | $9.10 | 78% | -0.24 | -3.26 | 66 |
| 672.5 | $10.00 | 78% | -0.26 | -3.45 | 61 |
| 677.5 | $11.20 | 76% | -0.30 | -3.59 | 1 |
| 680 | $12.60 | 78% | -0.33 | -3.83 | 6 |
| 700 | $22.60 | 80% | -0.53 | -4.33 | 1 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- 3 Biotech Stocks With Massive Upside to Buy Before August Starts10h ago
- Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs1d ago
- Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?1d ago
- 3 Cash-Heavy Stocks with Questionable Fundamentals2d ago
- Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight2d ago
- Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth2d ago
- Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics2d ago
- FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It2d ago
- Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins5d ago
- Regeneron Q2 Earnings Preview: Not Expecting Miracles - At Least In The Short Term5d ago
- Sanofi Drops Dupixent Successor Candidate After Assessing Data5d ago
- Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount5d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.